A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body.
Epistemonikos ID: 7650c547261d99c3ddac740772c0772e2e3ddee3
First added on: May 06, 2024